Case Study: Protocol KAN-101-02

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease

Study Objectives and Results

Objectives

  • Global Enrollment Goal: 104 Participants
  • QCR Enrollment Goal: 5 Participants
  • Enrollment Window: 6 Months
  • Target Population: Adults aged 19-70
  • Disease Characteristics: Previous Diagnosis of Celiac Disease

Quality Clinical Research achieved its enrollment goal 2 months before the enrollment window closed. Given this success, QCR was authorized to enroll beyond its initial target. This study had competitive enrollment and QCR outpaced average site enrollment. QCR’s contribution underscored its ability to exceed ambitious enrollment goals, reflecting its operational excellence.

Our Principal Investigator Dr. Brian Hollis and our Research Coordinator Jennifer Larsen were invited to sit on the Celiac Disease Foundation Site Advisory Council.

Result 01

7 Patients Enrolled

Result 02

6.7% of Trial Population

Result 03

Outpaced Average Site Enrollment

Scroll to Top